Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse model

Talya Shacham, Daniel Offen, Gerardo Z. Lederkremer*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Efficacy of therapy by MK-28 PERK activation in the Huntington's disease R6/2 mouse model'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science